Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 7:56 PM
Ignite Modification Date:
2025-12-24 @ 7:56 PM
NCT ID:
NCT01731704
Eligibility Criteria:
Inclusion Criteria:
* Pathologically (histologically or cytologically) proven diagnosis of a non-hematopoietic malignancy other than small cell lung cancer and germ cell malignancy within 5 years of registration. If the original histologic proof of malignancy is greater than 5 years, then pathological confirmation is required (e.g. from extra- or intra-cranial disease).
* If an open biopsy is performed, the patient must be at least one week post biopsy. This requirement does not apply to patients who undergo stereotactic biopsies.
* Patients with ≥5 measurable brain metastases on a diagnostic-quality contrast-enhanced magnetic resonance imaging (MRI) obtained within 30 days prior to registration.
* Patients with ≤10 cc largest tumor volume, and ≤15 cc total tumor volume.
* History/physical examination within 30 days prior to registration.
* Age ≥18 years.
* Karnofsky performance status ≥70 (RTOG recursive partitioning analysis (RPA) Class I \& II).
* Minimum pre-treatment oNCF score ≥70.
* Patients must provide study-specific informed consent prior to study entry.
* Women of child-bearing age must have a negative, quantitative serum pregnancy test ≤14 days prior to study entry, or have a documented reason why such a test is not necessary (e.g. history of tubal ligation).
* Patients must be able to speak and read English fluently (required for the use of online NCF testing).
* Patients must demonstrate basic computer literacy skills and have access to an internet terminal (required for the use of online NCF testing).
Exclusion Criteria:
* Clinical (e.g. multiple new cranial nerve deficits in the absence of obvious radiographic disease to explain symptoms) or radiographic evidence of leptomeningeal disease.
* Patients with measurable brain metastasis(es) resulting from small cell lung cancer and/or germ cell malignancy.
* No documentation of prior cytotoxic or other therapy for malignancy if such therapy was previously received. Note: This does not apply to patients with synchronous metastases at initial diagnosis.
* Contraindication to MR imaging, such as implanted metal devices or foreign bodies, severe claustrophobia, or contraindications to contrast agent administration.
* Estimated glomerular filtration rate (eGFR) \<60 within 6 weeks prior to registration. • Prior radiation therapy to the brain. • Severe, active co-morbidity, defined as follows:
* Unstable angina, and/or congestive heart failure requiring hospitalization within the last 6 months.
* Transmural myocardial infarction within the last 6 months. - Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration.
* Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects.
* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization, or precluding study therapy at the time of registration.
* Uncontrolled, clinically significant cardiac arrhythmias. - Radiologic or clinical evidence of hydrocephalus, or history of previously treated hydrocephalus.
* Women of childbearing potential and male participants who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the radiation treatment involved in this study is potentially teratogenic
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT01731704
Study Brief:
Protocol Section:
NCT01731704